FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1543-1545 October 11, 2007 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Ford, I. PubMed Citation

The development and progression of atherosclerosis is an intricate inflammatory process dependent on intimal entry of low-density lipoprotein (LDL) cholesterol. Although myriad genetic and environmental factors modulate this process, the centrality of LDL cholesterol to the physiology of plaque genesis, progression, and instability leads to the notion that reducing serum LDL cholesterol might be an effective way to mitigate or even prevent the disease.

A number of clinical trials have unequivocally demonstrated the clinical utility of lowering LDL cholesterol levels. The three major cholesterol-lowering trials carried out in people without a history of coronary events (primary prevention trials) include the . . . [Full Text of this Article]

Source Information

From the Atherothrombosis and Coronary Artery Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, MD.

This article has been cited by other articles:

• Steinberg, D., Glass, C. K., Witztum, J. L. (2008). Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia. Circulation 118: 672-677 [Full Text]  
• Deckelbaum, R. J, Leaf, A., Mozaffarian, D., Jacobson, T. A, Harris, W. S, Akabas, S. R (2008). Conclusions and recommendations from the symposium, Beyond Cholesterol: Prevention and Treatment of Coronary Heart Disease with n-3 Fatty Acids. Am. J. Clin. Nutr. 87: 2010S-2012S [Abstract] [Full Text]